FDA Approves First US Drug for Hepatitis Delta Treatment
The US Food and Drug Administration has approved bulevirtide (Hepcludex) for adults with chronic hepatitis delta virus infection, marking the first approved therapy option in the country.
Analytical Summary: Hepcludex — Victory Over FDA That Cost 4 Years and a Billion
Date: May 27, 2026
Event Source: FDA, Gilead Sciences, MYR301 (New England Journal of Medicine / The Lancet — database).
[Core Issue]: What's Really Happening
On May 22, 2026, the FDA finally approved bulevirtide (Hepcludex) for treating chronic hepatitis delta in adults. If you read press releases — it's just "the first drug in the US for a rare disease." If you look from the inside — it's a story of how the regulator nearly killed a drug due to bureaucracy, and Gilead lost $3.6 billion waiting.
To understand the scale: hepatitis delta (HDV) is not just "another virus." It is a satellite of hepatitis B (HBV) that turns ordinary hepatitis B deadly. Patients with co-infection have a 3–5 times higher risk of cirrhosis and hepatocellular carcinoma than those with HBV monoinfection. An estimated 40,000 to 80,000 people in the US live with this ticking time bomb. Until May 22, they had exactly zero FDA-approved therapy options.
Non-obvious insight (what they don't talk about):
Pay attention to the dosage. In Europe, bulevirtide is approved at 2 mg. In the US, Gilead applied for 10 mg, but the FDA approved 8.5 mg. The difference is not accidental. In 2022, the FDA rejected the drug not due to efficacy or safety — but due to "manufacturing and delivery" issues (CMC — chemistry, manufacturing, and controls). What does this mean in practice? It means Gilead couldn't convince the FDA that every dose from every batch would be identical. In 2022, Merck and Parsey (then Gilead's CMO) publicly expressed "disappointment." Behind that "disappointment" was a check for $3.6 billion — exactly what MYR GmbH would have cost if the drug had been approved on time.
Timeline and Context
Let's break down why approval took 4 years.
- July 2020: EMA grants conditional approval for bulevirtide in Europe. Europe rejoices — finally a therapy for delta hepatitis. Gilead realizes the US market is the main prize and prepares a BLA (Biologics License Application).
- October 2021: Gilead submits application to FDA. Status: breakthrough therapy, orphan drug. Everything goes according to plan.
- October 2022: FDA issues a Complete Response Letter (CRL) — rejection. Reason: "manufacturing and logistical issues." Not efficacy, not safety, but how the drug is produced and delivered. In the industry, this reads as: "You didn't provide product stability data under real-world conditions."
- 2023–2025: Gilead absorbs the blow. MYR GmbH (the German startup that originally developed the molecule) loses $3.6 billion in deferred payments. Meanwhile, real-world data accumulates in Europe — the French early access program (ATU) shows a 39% combined response on monotherapy.
- May 2026: FDA finally approves, but with conditions — accelerated approval, boxed warning about the risk of severe exacerbation upon discontinuation.
Who Wins and Who Loses
Winners:
- Gilead Sciences: Obviously. But not because they'll make money on Hepcludex (the US HDV market is at most $1–2 billion per year, pocket change for a giant). Rather, because they've closed the regulatory embarrassment of 2022. If the FDA had never approved it, it would have set a precedent undermining trust in Gilead's entire portfolio.
- Patients in the US: Finally, a legal option exists. Before this, people either flew to Europe for the drug (illegally), participated in clinical trials, or waited and died from cirrhosis.
- Hepatologists: Ira Jacobson from NYU Grossman School of Medicine has already given a quotable comment for Gilead's press release. For an academic career, being the first to prescribe a historic drug carries weight.
Losers:
- Competitors hoping to beat Gilead: Vir Biotechnology has a combination of tobevibart + elebsiran (Phase III), and Bluejay Therapeutics has brilovituge (Phase III). They hoped the FDA would never approve bulevirtide, making their drugs "first." Now they enter a race where Gilead already has first-mover advantage.
- Insurers (partially): The drug will be expensive. Although the exact US price hasn't been announced, in Europe a course costs tens of thousands of euros per year. Given that treatment may be lifelong (discontinuation risks fulminant hepatitis), it places a heavy burden on budgets.
What the Media Isn't Saying
- "Accelerated approval" is not full approval. The FDA gave the green light based on a surrogate endpoint — combined response (HDV RNA reduction + ALT normalization) at 48 weeks. The company must conduct a confirmatory study. If in a few years it turns out that viral load reduction doesn't correlate with reduced mortality or cirrhosis, the FDA will withdraw approval. This is not a hypothetical risk: it's happened with other drugs for other diseases.
- The black box is not a formality. The label states: "Discontinuation of treatment may lead to severe acute exacerbation of hepatitis D and B." What does this mean in practice? It means a patient who starts therapy cannot simply stop. If their insurance lapses, or they decide they "feel fine," or they have side effects — discontinuation can trigger fulminant liver failure. Doctors will think twice before prescribing this drug to patients with poor compliance.
- MYR301 numbers are impressive, but with nuances. Yes, at 144 weeks, 50% of patients achieved undetectable HDV RNA. But what about the 50% who didn't? They continue injecting the drug daily, for years, without guaranteed response. And let's be honest: daily subcutaneous injections are a huge burden on quality of life. Competing drugs (e.g., monoclonal antibodies) are administered every 2–4 weeks. Gilead has a time advantage, but not a convenience advantage.
Forecast: Next 30 Days and 90 Days
30 days:
There will be a wave of retrospective analyses and clinical guidelines. AASLD (American Association for the Study of Liver Diseases) will issue a practical guide for bulevirtide use. The price will be announced — I'm betting on $150,000 – $200,000 USD per year per patient (typical Gilead orphan drug pricing). Shares of Vir Biotechnology and Bluejay Therapeutics will drop 5–10% on competition news but quickly recover, as their combination regimens (antibody + siRNA) are potentially more potent.
90 days:
Enrollment will begin for the confirmatory Phase 4 study for the FDA. Key question: can bulevirtide be discontinued after achieving a sustained response? Current data show that upon discontinuation, the virus returns in most patients. Gilead will test a combination of bulevirtide + pegylated interferon, aiming for functional cure. If successful — the HDV market will change forever. If not — bulevirtide will remain a lifelong therapy, opening the door for competitors with more convenient dosing regimens.
Analyst Verdict: Congratulations to Gilead on winning the marathon. But the real battle for hepatitis delta is still ahead — and it will be won or lost in the field of combination therapies, not monotherapies. Hepcludex is an important first step, but not the last. Watch for the registration of the tobevibart + elebsiran combination — expect Phase III data in the first half of 2027. That's where a real breakthrough could happen.
— Editorial Team
